ArticleBirth defects research2026
Developmental Toxicity Evaluation of the Dietary Supplement Vinpocetine Using Mouse and Human 3D Gastruloids.
Article in Birth defects research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundVinpocetine is marketed as a dietary supplement for cognitive enhancement, despite the absence of regulatory requirements for comprehensive toxicity testing. The FDA has issued a warning against vinpocetine use by individuals of childbearing potential based on animal studies demonstrating impaired embryonic development. However, the relevance of these findings to human embryogenesis, as well as the contribution of vinpocetine's activity as a cyclic nucleotide metabolism modulator, remains unclear. To address these gaps, gastruloids derived from pluripotent stem cells may provide in vitro models of embryogenesis for investigating chemical impacts.
methodsGastruloids were generated from mouse P19C5 and human H9 pluripotent stem cells to evaluate the effects of vinpocetine, its major metabolite apovincaminic acid, and additional modulators of cyclic nucleotide metabolism. Morphological effects were measured using established morphometric parameters, and molecular effects were evaluated based on a previously validated panel of developmental regulator genes as sensitive biomarkers.
resultsVinpocetine induced distinct morphological changes in mouse gastruloids at concentrations ≥ 1 μM, whereas apovincaminic acid produced similar effects only at substantially higher concentrations. Other cyclic nucleotide-modulating compounds, including ITI-214, IBMX, forskolin, and cinaciguat, did not phenocopy vinpocetine-induced defects. In human gastruloids, vinpocetine impaired morphogenesis and altered developmental regulator expression at concentrations ≥ 0.2 μM.
conclusionsVinpocetine disrupts gastruloid development in both mouse and human models at concentrations commonly used to elicit purported neuroprotective effects, supporting animal-based evidence of developmental toxicity and demonstrating human relevance. These findings highlight reproductive safety concerns associated with vinpocetine and underscore the need for systematic toxicity evaluation of dietary supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.